Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Clay Siegall
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 247
- Beta
- 2.13
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 27.21
Financials
Revenue
$0.00-100.0%Net Income
$-73.13MEBITDA
$-72.17MFree Cash Flow
$-63.87MEPS (diluted)
$-0.65Shares Outstanding (diluted)
113.27M+10268.8%Operating Expenses
$78.14MCash & Debt
$520.00MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.94M | $-212.39M | $-2.43 |
| 2024 | $9.04M | $-292.96M | $-5.00 |
| 2023 | $14.02M | $-106.81M | $-5.38 |
| 2022 | $0.00 | $-36.90M | $-3.09 |
| 2021 | $0.00 | $-24.71M | $-2.14 |
| 2020 | $0.00 | $-17.84M | $-1.69 |
| 2019 | $0.00 | $-10.55M | $-1.84 |
| 2018 | $0.00 | $-7.84M | $-7.18 |
Valuation
IMNMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
37-47.62%Social Signal Score
Mentions (5)
- Newsbusinesswire.com·6d ago·Negative
… Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for th…
View source ↗ - Newsbusinesswire.com·34d ago·Positive
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.Interested parties can access the live audio webcast of the presentatio…
View source ↗ - Newsmarketbeat.com·50d ago·Positive
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
View source ↗ - Newsglobenewswire.com·50d ago·Positive
… ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy argenx to host a conference ca…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat's NDA and a PDUFA date set for April 2027. The company's pipeline is diversified, with IM-1021 [ROR1 ADC] in phase 1 for B-cell lymphoma/solid tumors and initial data expected in 2026. The proprietary HC74 TOP1i payload in IM-1021 aims for best-in-class efficacy, targeting resistance and bystander effect…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.65 per share
Typical surprise -14.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.65 vs $-0.51miss
- Tue, May 12$-0.48 vs $-0.60beat
- Tue, Mar 3$-0.75 vs $-0.59miss
- Thu, Nov 6$-0.65 vs $-0.57miss
- Wed, Aug 6$-0.50 vs $-0.52beat
- Mon, May 12$-0.52 vs $-0.66beat
Estimates and results for IMNM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMNM officers and directors.
- Bought
- $2.4m
- Sold
- $27.5m
12 trades
28 trades
- Higgins Jacksold
- Barchas Isaacsold
- Barchas Isaacsold
- Barchas Isaacsold
- Barchas Isaacsold
- Barchas Isaacsold
- Horn Kinneysold
- Horn Kinneysold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMNM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.